Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination With Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer

Next Previous
X
Search
Trial Profile

A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination With Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Enfortumab vedotin (Primary)
  • Indications Carcinoma; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 13 Aug 2024 Planned End Date changed from 21 Jan 2025 to 21 Jan 2026.
    • 04 Jun 2024 Preliminary results ( As of the 6 January 2024, n=10) assessing safety and preliminary efficacy data from the dose escalation and currently accruing dose expansion cohort of an ongoing phase I/Ib trial investigating cabo in combination with EV in patients (pts) with mUC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 27 Jan 2024 Interim results (As of the 22 September 2023; n=6) assessing safety and preliminary efficacy data from the dose escalation cohort in metastatic urothelial cancer, presented at the 2024 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top